A pharmacologic approach to obesity
- New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564
The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...
- Anti-obesity drug use before professional treatment in Taiwan. Tsan-Hon Liou; Chih-Hsing Wu; Hsu-Chen Chien; Wen-Yuan Lin; Wei-Jei Lee; Pesus Chou // Asia Pacific Journal of Clinical Nutrition;Sep2007, Vol. 16 Issue 3, p580
Between July 2004 and June 2005, a cross-sectional study was performed to determine the prevalence and patterns of anti-obesity medicine use among subjects seeking obesity treatment in Taiwan. Eighteen obesity outpatient clinics were selected via a random stratified sampling method and 1,060...
- Obesity drug endorsed by NICE. Wise, Jacqui // BMJ: British Medical Journal (International Edition);03/17/2001, Vol. 322 Issue 7287, p637
Reports on the possible availability of the anti-obesity drug orlistat (Xenical) throughout England and Wales on the National Health Service. Decision made by the National Institute for Clinical Excellence (NICE); Guidelines for prescribing orlistat, as one part of the management of obesity;...
- WEIGHT WATCHER. Springen, Karen // Newsweek;2/6/2006, Vol. 147 Issue 6, p70
This article discusses the pros and cons of taking the weight loss drug orlistat, a medication which is marketed by Roche and is sold under the name of Xenical. Orlistat is prescribed by doctors as a weight loss drug and is typically recommended only for those patients suffering from...
- Orlistat: A Viewpoint by F. Xavier Pi-Sunyer. Pi-Sunyer, F.X. // Drugs;Aug1998, Vol. 56 Issue 2, p250
Offers views on the anti-obesity drug orlistat. Mechanism of actio; Toxicity; Effectiveness.
- Orlistat: A Viewpoint by Madeleine L. Drent. Drent, M.L. // Drugs;Aug1998, Vol. 56 Issue 2, p250
Offers views on the anti-obesity drug orlistat. Physiological effects of orlistat; Effectiveness; Adverse effects.
- Orlistat. McNeely, W.; Benfield, P. // Drugs;Aug1998, Vol. 56 Issue 2, p241
â–´ Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity. â–´ Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in...
- Orlistat. // Reactions Weekly;9/17/2011, Issue 1369, p30
The article describes the case of a woman who developed a lichenoid drug eruption (LDE) following treatment with orlistat for obesity.
- Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities. Sangmi Oh; Koon Soon Kim; Young Sun Chung; Minho Shong; Seung Bum Park // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p466
In addition to its enormous impacts on an individual's quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the...